ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
PCSK9 and Breast Cancer Survival: A Mendelian Randomization Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) affects lipid metabolism. A recent study identified an association between rs562556 within the PCSK9 gene and breast cancer survival (BCS), suggesting PCSK9 inhibition as an early intervention strategy to prevent metastasizing breast cancer. We attempt to replicate these findings using genome-wide association study (GWAS) data and Mendelian Randomization (MR).
methodsWe used GWAS data from the Breast Cancer Association Consortium (BCAC, N = 91,686) and performed analyses in the FinnGen study (N = 4,648; additive and recessive model). First, we tested the association of the single variant rs562556, then genetically proxied PCSK9 inhibition using multiple variants, and finally adjusted for the indirect effects of lipid metabolism using multivariable MR. Coronary artery disease was chosen as a positive control outcome.
resultsEstimates are scaled as log hazard ratios (logHR) per 1 SD higher PCSK9 levels. We found no significant association between PCSK9 variants and BCS in any MR approach with any replication data: single variant [BCAC: logHR = 2.37, P = 0.066; FinnGen additive: logHR = 0.58, P = 0.91; FinnGen recessive: logHR = -2.75, P = 0.87], multiple variants [BCAC: logHR = -0.22, P = 0.30; FinnGen: logHR = -0.40, P = 0.54], or multivariable [BCAC: logHR = 0.42, P = 0.65; FinnGen: logHR = 1.23, P = 0.75]. Positive control analyses were significant throughout.
conclusionsA significant association of PCSK9 variants with BCS could only be reproduced using outcome data from the original study but not when using independent, larger GWASs. IMPACT: Potential reasons for the discrepant results are different genetic models, sample selection criteria, and the time variability of HR estimates. They should be explored before considering PCSK9, a therapeutic target in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.